Cargando…

Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy

The clinical use of anti-CD40 agonist monoclonal antibodies (mAbs) is aimed at recruiting the immune system to fight the tumor cells. This approach has been demonstrated to be effective in various preclinical models. However, human CD40 Abs displayed only modest antitumor activity in cancer patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salomon, Ran, Dahan, Rony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326085/ https://www.ncbi.nlm.nih.gov/pubmed/35911742 http://dx.doi.org/10.3389/fimmu.2022.940674

Ejemplares similares

ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
por: Mangsbo, Sara M, et al.
Publicado: (2013)

Agonistic CD40 Antibodies in Cancer Treatment
por: Djureinovic, Dijana, et al.
Publicado: (2021)

Next Generation Natural Killer Cells for Cancer Immunotherapy
por: Rossi, Fiorella, et al.
Publicado: (2022)

Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer
por: Sandin, Linda C, et al.
Publicado: (2014)

Agonistic Anti-CD40 Antibody Triggers an Acute Liver Crisis With Systemic Inflammation in Humanized Sickle Cell Disease Mice
por: Yalamanoglu, Ayla, et al.
Publicado: (2021)

Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display
por: Krohn, Steffen, et al.
Publicado: (2022)

Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors
por: Yu, Tao, et al.
Publicado: (2022)

Editorial: Next generation γδ T cell-based tumor immunotherapy
por: Tan, Andy Hee-Meng, et al.
Publicado: (2022)

The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy
por: Frankish, Jamie, et al.
Publicado: (2023)

Next-Generation Sequencing of Antibody Display Repertoires
por: Rouet, Romain, et al.
Publicado: (2018)

Developing a translational murine‐to‐canine pathway for an IL‐2/agonist anti‐CD40 antibody cancer immunotherapy
por: Proksch, Stephen Francis, et al.
Publicado: (2022)

Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?
por: Ben-Shmuel, Aviad, et al.
Publicado: (2020)

Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines
por: Ceglia, Valentina, et al.
Publicado: (2022)

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
por: Yang, Yan, et al.
Publicado: (2021)

The Application of Next Generation Sequencing to the Understanding of Antibody Repertoires
por: Mathonet, Pascale, et al.
Publicado: (2013)

Plasma Cells, the Next Generation: Beyond Antibody Secretion
por: Pioli, Peter D.
Publicado: (2019)

CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches
por: Argiriadi, Maria A., et al.
Publicado: (2019)

Development of OX40 agonists for canine cancer immunotherapy
por: Ruiz, Damien, et al.
Publicado: (2022)

Platelets as Key Factors in Inflammation: Focus on CD40L/CD40
por: Cognasse, Fabrice, et al.
Publicado: (2022)

Radiation and Local Anti-CD40 Generate an Effective in situ Vaccine in Preclinical Models of Pancreatic Cancer
por: Yasmin-Karim, Sayeda, et al.
Publicado: (2018)

Natural killer cells: the next wave in cancer immunotherapy
por: Chen, Xin, et al.
Publicado: (2022)

Combination Immunotherapy: Taking Cancer Vaccines to the Next Level
por: Grenier, Jeremy M., et al.
Publicado: (2018)

The Contribution of CD40/CD40L Axis in Inflammatory Bowel Disease: An Update
por: Senhaji, Nezha, et al.
Publicado: (2015)

The CD40–CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
por: Aarts, Suzanne A. B. M., et al.
Publicado: (2017)

Generation of Human B-Cell Lines Dependent on CD40-Ligation and Interleukin-4
por: Banchereau, Jacques
Publicado: (2015)

Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy
por: Chakraborty, Samik, et al.
Publicado: (2023)

The human CD40 agonistic antibody ADC-1013 generates immune mediated anti-tumor effects in syngeneic tumor models in hCD40 transgenic mice
por: Mangsbo, Sara M, et al.
Publicado: (2014)

Insights into the Structural Basis of Antibody Affinity Maturation from Next-Generation Sequencing
por: Mishra, Arjun K., et al.
Publicado: (2018)

Next-Generation Anti-Angiogenic Therapies as a Future Prospect for Glioma Immunotherapy; From Bench to Bedside
por: Shamshiripour, Parisa, et al.
Publicado: (2022)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

Involvement of CD40-CD40L and ICOS-ICOSL in the development of chronic rhinosinusitis by targeting eosinophils
por: Zhou, Aina, et al.
Publicado: (2023)

Pre-clinical development of the human CD40 agonistic antibody ADC-1013
por: Norlén, Per, et al.
Publicado: (2015)

Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive Macrophages
por: Murgaski, Aleksandar, et al.
Publicado: (2022)

Acute Hemolysis and Heme Suppress Anti-CD40 Antibody-Induced Necro-Inflammatory Liver Disease
por: Pfefferlé, Marc, et al.
Publicado: (2021)

Emergence of the CD226 Axis in Cancer Immunotherapy
por: Conner, Michael, et al.
Publicado: (2022)

Editorial: CD4(+) T Cells in Cancer Immunotherapies
por: González-Navajas, José M., et al.
Publicado: (2021)

TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory Effects
por: Lu, Hailing
Publicado: (2014)

Editorial: Next-Generation Sequencing of Human Antibody Repertoires for Exploring B-cell Landscape, Antibody Discovery and Vaccine Development
por: Prabakaran, Ponraj, et al.
Publicado: (2020)

Next-generation cytokines for cancer immunotherapy
por: Xue, Diyuan, et al.
Publicado: (2021)

Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies
por: Li, Da-Ke, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c4cs5dfkhg52dlusuo2f9ke0cv